Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy

Abstract Malignant cutaneous melanoma is one of the most common cancers in young adults. During last decade, targeted and immunotherapies have significantly increased overall survival patients with malignant melanoma. Nevertheless, disease progression common, a lack predictive biomarkers patient response to therapy hinders individualized treatment strategies. To address this issue, we performed longitudinal study using an unbiased proteomics approach identify quantify proteins plasma both before during from 109 treated either or immunotherapy. Linear modeling machine learning approaches identified 43 potential prognostic biomarkers. A reverse correlation between apolipoproteins related inflammation was observed. In immunotherapy group, low pretreatment expression high markers had shorter progression-free survival. Similarly, LDHB elicited significant impact on Overall, treatment-specific melanoma, paving way for clinical use these following validation larger cohort. Significance: This identifies biomarker panel that could improve selection